Company logo

TH - Theratechnologies Inc.

TSX -> Healthcare -> Drug Manufacturers—Specialty & Generic
Montreal, Canada
Type: Equity

TH price evolution
TH
(in millions $) 31 May 2024 29 Feb 2024 30 Nov 2023 31 Aug 2023
Current assets
Cash $31.17 $32.24 $34.1 $14.97
Short term investments $4.86 $6.21 $6.76 $7.91
Net receivables $13.56 $10.5 $13.55 $9.12
Inventory $5.53 $6.3 $6.07 $6.72
Total current assets $57.33 $57.94 $63.3 $40.56
Long term investments
Property, plant & equipment $0.92 $1.82 $1.98 $2.19
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $70.21 $72.09 $77.77 $56.69
Current liabilities
Accounts payable $26.28 $29.93 $6.99 $30.46
Deferred revenue
Short long term debt $17.9 $12.78 $7.71 $57.56
Total current liabilities $51.98 $50.32 $47.29 $97.66
Long term debt $41.42 $46.36 $51.26 $0.68
Total noncurrent liabilities
Total debt
Total liabilities $93.42 $96.69 $98.64 $98.39
Shareholders' equity
Retained earnings -$412.15 -$413.14 -$408.66 -$403.85
Other shareholder equity $0.8 $0.74 $0.68 $0.59
Total shareholder equity -$23.21 -$24.6 -$20.87 -$41.7
(in millions $) 30 Nov 2023 31 Jan 2023 30 Nov 2021 30 Nov 2020
Current assets
Cash $34.1 $23.86 $40.35 $12.74
Short term investments $6.76 $10.56 $22.98 $8.03
Net receivables $13.55 $42.15 $10.93 $13.19
Inventory $6.07 $19.69 $29.14 $25.14
Total current assets $63.3 $236.38 $91.91 $64.81
Long term investments
Property, plant & equipment $1.98 $416.32 $2.85 $3.48
Goodwill & intangible assets
Total noncurrent assets $490.68
Total investments
Total assets $77.77 $771.73 $119.21 $100.14
Current liabilities
Accounts payable $6.99 $17.56 $15.53 $17.51
Deferred revenue $6.62
Short long term debt $7.71 $65.26 $0.46 $5.09
Total current liabilities $47.29 $190.9 $45.08 $41.92
Long term debt $51.26 $329.94 $56.28 $54.96
Total noncurrent liabilities $389.82
Total debt
Total liabilities $98.64 $570.88 $101.45 $96.92
Shareholders' equity
Retained earnings -$408.66 $87.68 -$335.25 -$300.13
Other shareholder equity $0.68 -$2.57 $4.41 $3.98
Total shareholder equity -$20.87 -$22.57 $17.76 $3.22
(in millions $) 30 Oct 2024 31 May 2024 29 Feb 2024 30 Nov 2023
Revenue
Total revenue $22.02 $16.25 $23.45
Cost of revenue $4.55 $5.28 $5.07
Gross Profit $17.47 $10.96 $18.39
Operating activities
Research & development $4.72 $3.75 $4.35
Selling, general & administrative $9.46 $9.46 $7.61
Total operating expenses $18.73 $18.49 $19.54
Operating income $3.29 -$2.25 $3.91
Income from continuing operations
EBIT
Income tax expense $0.12 $0.11 $0.07
Interest expense -$2.7 -$2.65 -$3.77
Net income
Net income $0.99 -$4.48 -$2.76
Income (for common shares) $0.99 -$4.48 -$2.76
(in millions $) 30 Nov 2023 30 Nov 2022 30 Nov 2021 30 Nov 2020
Revenue
Total revenue $81.76 $80.06 $69.82 $66.05
Cost of revenue $19.64 $23.84 $23.26 $27.81
Gross Profit $62.13 $56.22 $46.56 $38.24
Operating activities
Research & development $28.99 $36.94 $28.27 $18.02
Selling, general & administrative $39.29 $50.39 $40.34 $36.14
Total operating expenses $90.43 $113.61 $95.06 $84.01
Operating income -$8.66 -$33.55 -$25.24 -$17.96
Income from continuing operations
EBIT
Income tax expense $0.42 $0.44 $0.06 $0.02
Interest expense -$11.32 -$6.5
Net income
Net income -$23.96 -$47.24 -$31.73 -$22.67
Income (for common shares) -$23.96 -$47.24 -$31.73 -$22.67
(in millions $) 31 May 2024 29 Feb 2024 30 Nov 2023 31 Aug 2023
Net income $0.99 -$4.48 -$2.76 -$0.75
Operating activities
Depreciation $0.9 $0.16 $0.22 $0.19
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$0.29 -$1.71 -$4.11 $5.33
Investing activities
Capital expenditures -$0.01
Investments
Total cash flows from investing -$0.14 $0.13 $0.14 $0.56
Financing activities
Dividends paid
Sale and purchase of stock $25.16
Net borrowings -$0.12 -$0.12 -$0.12 -$7.56
Total cash flows from financing -$0.64 -$0.28 $23.09 -$7.91
Effect of exchange rate -$0.04 -$0 $1.21 -$0.03
Change in cash and equivalents -$1.07 -$1.86 $19.13 -$1.99
(in millions $) 30 Nov 2023 30 Nov 2022 30 Nov 2021 30 Nov 2020
Net income -$23.96 -$47.24 -$31.73 -$22.67
Operating activities
Depreciation $0.8 $0.82 $0.69 $0.69
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$5.68 -$14.69 -$14.48 -$13.55
Investing activities
Capital expenditures -$0.32 -$0.98 -$0.17 -$0.03
Investments
Total cash flows from investing $1.11 $8.68 -$12.45 $4.78
Financing activities
Dividends paid
Sale and purchase of stock $25.16 $2.98 $47.34 $0.14
Net borrowings -$7.9 $10.65 -$5.63 -$4.07
Total cash flows from financing $14.78 $9.66 $34.56 -$7.23
Effect of exchange rate $1.1 -$1.03 $0.04 $0.08
Change in cash and equivalents $10.24 $3.46 $7.66 -$15.92
News
Theratechnologies Inc (THTX) Q3 2024 Earnings Call Highlights: Strong...
GuruFocus.com · via Yahoo Finance 19 Oct 2024
Earnings to Watch: Theratechnologies Inc (TSX:TH) Reports Q3 2024 Result
GuruFocus.com · via Yahoo Finance 7 Oct 2024
Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug,...
Benzinga · via Yahoo Finance 20 Sep 2024
HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock...
Benzinga · via Yahoo Finance 20 Jul 2024
Theratechnologies Inc. (TSE:TH) Has Found A Path To Profitability
Simply Wall St. · via Yahoo Finance 19 Jun 2024
Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?
Zacks · via Yahoo Finance 18 Apr 2024
Elina Tea joins Theratechnologies board and audit committee
Investing.com 5 Apr 2024
Theratechnologies Full Year 2023 Earnings: Misses Expectations
Simply Wall St. · via Yahoo Finance 16 Feb 2024
Positive Signs As Multiple Insiders Buy Theratechnologies Stock
Simply Wall St. via Yahoo Finance 28 Jan 2024
10 Oversold Canadian Stocks To Buy
Insider Monkey via Yahoo Finance 5 Aug 2023
Fundamentals
Market cap $168.72M
Enterprise value N/A
Shares outstanding 100.43M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio -7.03
Book/Share -0.24
Cash/Share 0.31
EPS N/A
ROA N/A
ROE N/A
Debt/Equity -4.73
Net debt/EBITDA N/A
Current ratio 1.10
Quick ratio 1.00